CyDex Pharmaceuticals Initiates Dosing for Phase 2A Oncology Drug Trial
LENEXA, Kansas--(BUSINESS WIRE)--CyDex Pharmaceuticals, Inc. today announced the initiation of patient dosing in the company’s Phase 2A clinical trial of its Captisol-Enabled® Melphalan HCL (CDX-353). Melphalan is an FDA-approved chemotherapy for the palliative treatment of multiple myeloma marketed under the brand name Alkeran® by GlaxoSmithKline.